Testing benralizumab in children with eosinophil diseases
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This trial tests a medicine called benralizumab for children with specific eosinophil-driven diseases (EGPA or HES). It aims to see if the drug can help control these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 and 17 years old.
- Your child must weigh at least 15 kilograms (33 pounds).
- Your child must have either EGPA or HES (certain types of eosinophil disorders).
- Your child cannot have a history of cancer, serious allergies to biologic drugs, or other major organ problems.
- Your child must not have received benralizumab before in a clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial lets people who completed an earlier benralizumab study and are benefiting from the medicine keep receiving it. The goal is to provide ongoing access while we continue to monitor safety and effectiveness.
This trial studies different types of eosinophil cells in people with asthma, eosinophilic granulomatosis with polyangiitis (EGPA), or hypereosinophilic syndrome (HES). It also includes healthy volunteers. The goal is to better understand these cells in each condition.
This trial tests reslizumab, a medicine that targets a specific immune signal, to improve symptoms in people with eosinophilic granulomatosis with polyangiitis (EGPA). It may help lower disease activity and reduce inflammation-related problems.
This study tests if adding a new injectable medicine (benralizumab) to your current medium-dose inhaler works better than simply increasing your inhaler dose to control hard-to-treat asthma. It may help people with a specific type of asthma linked to high eosinophil levels.
This trial tests if dupilumab, added to your current treatment, can help with remaining symptoms of hypereosinophilic syndrome (HES) like asthma, eczema, nasal polyps, or eosinophilic esophagitis. You may qualify if you're already on a biologic therapy that lowers eosinophils but still have bothersome symptoms.
This trial studies whether a specific “signature” from asthma tests can predict who will respond to benralizumab (a severe asthma biologic). If you qualify, the researchers will compare your test results to how well benralizumab controls your asthma and prevents flare-ups.
Hear when a new Eosinophilic Granulomatosis With Polyangiitis (EGPA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.